Guangzhou Huirui Pharmaceutical Technology Development

Guangzhou Huirui Pharmaceutical Technology Development is a clinical-stage biopharmaceutical company headquartered in Guangzhou, China, specializing in the discovery and development of innovative small molecule therapeutics. The company focuses on high-prevalence diseases including metabolic disorders, oncology, and autoimmune conditions. Its lead program, HR1405-01, is a highly selective URAT1 inhibitor currently undergoing Phase 2 clinical trials for the treatment of hyperuricemia and gout. Guangzhou Huirui's pipeline also includes HR1901, a selective JAK3/TEC inhibitor for hematological malignancies, and HR1801, an SGLT2 inhibitor for type 2 diabetes. By leveraging its internal R&D capabilities, the company aims to deliver effective and accessible medical solutions to patients in the Chinese market and beyond.